Martha Stewart Insider Trading Case: What Actually Happened

Introduction

The Martha Stewart case is one of the most misunderstood episodes in the history of securities enforcement. Almost everyone knows that Martha Stewart went to prison for something related to insider trading. What most people get wrong is the specific charge: Stewart was never charged with insider trading. She was convicted of conspiracy, obstruction of justice, and making false statements to federal investigators — crimes that stemmed not from the stock sale itself, but from her attempt to cover it up afterward.

The case is a cautionary tale about how the cover-up can be far more damaging than the underlying conduct, and about how a relatively small financial transaction — Stewart’s profit from the sale was less than $50,000 — can spiral into a criminal prosecution that destroys reputations and sends people to prison.

This is the full story of what happened, who was involved, and what it means for investors and market participants.

The Setup: ImClone Systems and Erbitux

ImClone Systems was a biopharmaceutical company that had developed a promising cancer drug called Erbitux (generic name: cetuximab). Erbitux was designed to treat colorectal cancer by targeting the epidermal growth factor receptor (EGFR), a protein involved in tumor growth. The drug had shown encouraging results in clinical trials, and ImClone had submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for approval.

The company’s stock price was heavily tied to the FDA’s decision on Erbitux. An approval would validate the company’s technology platform and likely send the stock soaring. A rejection would be devastating. By late December 2001, ImClone was trading around $60 per share, with investors optimistic about the drug’s prospects.

The CEO of ImClone was Sam Waksal, a charismatic scientist-entrepreneur who had founded the company in 1984. Waksal was well-connected in New York social circles and counted Martha Stewart among his friends. Both Waksal and Stewart held brokerage accounts at Merrill Lynch, and both were clients of the same broker: Peter Bacanovic.

December 27, 2001: The Trade

On December 27, 2001, Sam Waksal learned that the FDA was going to reject ImClone’s application for Erbitux. The agency had determined that ImClone’s application was incomplete — the company had not provided adequate data from its clinical trials. This was devastating news that, once public, would cause ImClone’s stock to plummet.

Waksal immediately tried to sell his own ImClone shares. He also instructed members of his family to sell their shares. His attempts were clumsy and obvious — he tried to transfer shares to his daughter’s account and then sell them, a transaction that Merrill Lynch’s compliance department actually blocked.

Douglas Faneuil, Bacanovic’s 26-year-old assistant, called Martha Stewart and informed her that Waksal and his family were selling their ImClone shares. Stewart was traveling at the time, en route to a vacation in Mexico. Upon receiving the call, she instructed Faneuil to sell all of her ImClone shares.

Stewart sold all 3,928 shares of ImClone Systems at approximately $58 per share, receiving about $228,000 in proceeds. The next day, December 28, 2001, the FDA publicly announced its rejection of ImClone’s Erbitux application. ImClone’s stock dropped 16% that day. By selling the day before, Stewart had avoided losses of approximately $45,673.

The Cover-Up

When the SEC and federal prosecutors began investigating the suspicious timing of Stewart’s trade, Stewart and her broker Peter Bacanovic concocted a story: they claimed that Stewart had a pre-existing agreement with Bacanovic to sell her ImClone shares if the stock price fell below $60 per share. This was, essentially, a claim that she had a standing stop-loss order.

This story was false. There was no pre-existing stop-loss agreement. The sale was triggered entirely by Faneuil’s call informing Stewart that Waksal was selling.

On February 4, 2002, Stewart spoke with investigators from the SEC, the FBI, and the U.S. Attorney’s Office. During this interview, she repeated the false story about the stop-loss agreement. She stated that she and Bacanovic had agreed in advance that she would sell her ImClone shares if the price fell to $60. This statement was a lie, and it was this lie — not the stock sale itself — that would ultimately send her to prison.

Bacanovic backed up Stewart’s story and went further, altering a worksheet in an attempt to create documentary evidence of the $60 stop-loss order. But the cover story began to unravel when Douglas Faneuil, under pressure from investigators, decided to tell the truth. Faneuil admitted that he had tipped Stewart about Waksal’s selling activity at Bacanovic’s direction, and that there had been no pre-existing stop-loss agreement.

Sam Waksal: The Source

Sam Waksal’s case was straightforward. As the CEO of ImClone, he had learned about the FDA rejection before it was publicly announced and had immediately tried to sell his shares and tip off his family members. This was textbook insider trading — a corporate insider trading on material nonpublic information.

Waksal did not contest the charges. He pleaded guilty to securities fraud, conspiracy, obstruction of justice, and bank fraud (he had also lied to a bank to obtain a loan). On June 10, 2003, he was sentenced to seven years and three months in federal prison and ordered to pay more than $4 million in fines and penalties. He also agreed to a lifetime ban from serving as an officer or director of a public company.

It is worth noting the irony of Waksal’s situation. Erbitux was eventually approved by the FDA in 2004 — after ImClone’s application was revised and resubmitted with adequate clinical data. The drug went on to become a significant commercial success. Had Waksal simply held his shares and waited, he would have profited enormously. Instead, his panicked attempt to sell ahead of the initial rejection cost him his freedom, his career, and his company.

The Trial: United States v. Martha Stewart

Martha Stewart and Peter Bacanovic were indicted in June 2003. The charges against Stewart were:

1. Conspiracy — conspiring with Bacanovic to obstruct the investigation
2. Obstruction of justice — impeding the SEC and DOJ investigation
3. Two counts of making false statements — lying to federal investigators about the reason for her stock sale

The trial began on January 20, 2004, in the U.S. District Court for the Southern District of New York. It lasted approximately six weeks. The prosecution’s star witness was Douglas Faneuil, who testified in detail about the phone call in which he tipped Stewart about Waksal’s selling activity. Faneuil also testified about Bacanovic’s role in directing the tip and the subsequent cover-up.

Stewart’s defense team argued that the government had not proven that her statements were intentionally false, and that her recollection of a stop-loss agreement could have been a genuine memory of a conversation she had with Bacanovic at some earlier point. The defense also emphasized the small size of the transaction relative to Stewart’s overall wealth — the $45,673 in avoided losses was trivial for a woman worth hundreds of millions of dollars.

On March 5, 2004, the jury found Martha Stewart guilty on all four counts: one count of conspiracy, one count of obstruction of justice, and two counts of making false statements. Peter Bacanovic was also convicted on four of the five counts against him.

The Sentence

On July 16, 2004, Judge Miriam Goldman Cedarbaum sentenced Martha Stewart to five months in federal prison, five months of home confinement, and two years of supervised release. She was also fined $30,000. The sentence was at the low end of the federal sentencing guidelines, reflecting the relatively minor nature of the underlying conduct and Stewart’s lack of prior criminal history.

Stewart reported to the Federal Prison Camp at Alderson, West Virginia — a minimum-security women’s facility sometimes referred to as “Camp Cupcake” by the media — on October 8, 2004. She was released on March 4, 2005, after serving her five-month sentence.

The SEC Civil Case

In addition to the criminal prosecution, the SEC filed a civil enforcement action against Stewart. In August 2006, Stewart settled the SEC’s civil charges without admitting or denying the allegations. Under the settlement, she agreed to pay $195,081 — which represented disgorgement of the $45,673 in losses she avoided by selling, plus a penalty of three times that amount ($136,952), plus prejudgment interest of $12,456. She also agreed to a five-year ban from serving as a director or officer of a public company.

Peter Bacanovic and Douglas Faneuil

Peter Bacanovic, the Merrill Lynch broker who orchestrated the tip to Stewart and participated in the cover-up, was convicted alongside Stewart. He was sentenced to five months in federal prison and five months of home confinement, the same sentence as Stewart. He was also fined $4,000 and permanently barred from the securities industry by the SEC.

Douglas Faneuil, the young assistant who actually made the phone call to Stewart, cooperated with prosecutors from early in the investigation. His cooperation was crucial to the government’s case. In exchange for his testimony, Faneuil pleaded guilty to a single misdemeanor charge of receiving and giving gifts in connection with the tip. He was sentenced to a $2,000 fine and no prison time.

The Aftermath: Stewart’s Comeback

What happened after Martha Stewart’s release from prison was almost as remarkable as the case itself. Rather than destroying her brand, the prosecution and imprisonment had the paradoxical effect of generating enormous public sympathy and media attention.

The stock price of Martha Stewart Living Omnimedia (MSO), which had fallen sharply after her indictment, actually rose significantly in the period surrounding her release. The company’s stock price had been under $8 during the trial and climbed above $30 in early 2005, partly on speculation that Stewart’s return would revitalize the brand.

Stewart launched a new television show, “The Martha Stewart Show,” and returned to her role as the public face of her media and merchandising empire. She appeared on “The Apprentice: Martha Stewart” on NBC. While the conviction remained a permanent part of her record, she successfully rebuilt her public image and business career.

In 2015, Sequential Brands Group acquired Martha Stewart Living Omnimedia for approximately $353 million. Stewart continued to expand her brand through partnerships, including a notably successful collaboration with Snoop Dogg on the VH1 show “Martha & Snoop’s Potluck Dinner Party.”

What the Case Teaches Us

The cover-up is worse than the crime

The single most important lesson from the Martha Stewart case is that lying to federal investigators is almost always a worse decision than the underlying conduct being investigated. Stewart’s avoided losses of $45,673 were financially trivial for someone of her wealth. Had she simply told investigators the truth — or, better yet, declined to speak with them and retained a lawyer — there is a reasonable possibility that she would never have been charged criminally. The government’s case for insider trading against Stewart was weak, as evidenced by the fact that they chose not to bring those charges. It was only her false statements that gave prosecutors the clear-cut criminal case they needed.

The tip chain matters

Stewart’s case also illustrates how insider information can flow through intermediaries. The original inside information (the FDA rejection) was known to Sam Waksal. Waksal’s selling activity was observed by Peter Bacanovic. Bacanovic directed Faneuil to tell Stewart that Waksal was selling. Stewart then made her trade. At each step in this chain, the information became slightly more removed from the original source, but each participant still faced legal exposure.

Compliance procedures exist for a reason

It is worth noting that Merrill Lynch’s compliance department actually blocked some of Waksal’s attempted transactions, recognizing them as suspicious. The firm’s internal controls worked as intended in that instance. But the tip to Stewart went through informal channels — a phone call from a junior assistant — that bypassed the firm’s compliance infrastructure.

Small amounts, big consequences

Perhaps the most striking aspect of the case is the disproportion between the financial amount at stake and the consequences that followed. Stewart avoided losing approximately $45,673. In exchange, she endured a federal investigation, a public trial, a criminal conviction, five months in prison, five months of home confinement, $195,081 in SEC penalties, a $30,000 criminal fine, a five-year ban from serving as a public company director, and incalculable damage to her personal reputation and business empire. No reasonable cost-benefit analysis would ever support the decision to lie to investigators over such a relatively small amount of money.

The Broader Impact on Securities Enforcement

The Stewart case had a significant impact on public awareness of insider trading laws. Because of Stewart’s celebrity status, the case received far more media coverage than a typical securities prosecution, and it brought the concept of insider trading into mainstream public consciousness in a way that few previous cases had.

The case also reinforced the SEC’s willingness to pursue high-profile targets. Prosecuting Martha Stewart was a bold decision — she was an enormously popular public figure, and there was no guarantee that a jury would convict. The successful prosecution sent a message that no one was too famous or too powerful to face securities enforcement action.

For investors, the case underscores the importance of making trading decisions based on publicly available information. The legally required SEC filings that corporate insiders make — Form 4 filings disclosing their stock purchases and sales — provide a wealth of information that anyone can use to inform their investment decisions, entirely within the bounds of the law.